IPH-5301

N/A

Report date: 2025/03/19 16:04:17

Base Information

Drug NameIPH-5301
Drug Alias NameIPH-5301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of Action5'-nucleotidase inhibitors
Targets5'-nucleotidase
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesInnate Pharma
China Registration ClassN/A

Develop Information

Active CompaniesInnate PharmaInstitut Paoli-Calmettes
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursNeoplasm Metastasis +[9] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A